Propanoic acid, 2-methyl-, 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester, (2E)-2-butenedioate (1:1)
| Title | Journal |
|---|---|
| Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation. | International urogynecology journal 20121101 |
| Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. | Expert opinion on drug metabolism & toxicology 20121101 |
| Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. | Neurourology and urodynamics 20121101 |
| Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. | International urogynecology journal 20121001 |
| Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. | International journal of clinical pharmacology and therapeutics 20121001 |
| Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. | BJU international 20120801 |
| Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder. | Journal of pediatric urology 20120801 |
| Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. | Annals of internal medicine 20120619 |
| Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. | BJU international 20120601 |
| Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial. | American journal of obstetrics and gynecology 20120501 |
| Evaluation of cognitive function in healthy older subjects treated with fesoterodine. | Postgraduate medicine 20120501 |
| Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. | Drugs & aging 20120201 |
| The psychometric validation of a 1-week recall period for the OAB-q. | International urogynecology journal 20111201 |
| Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. | Neurourology and urodynamics 20111101 |
| Review of fesoterodine. | Expert opinion on drug safety 20110901 |
| Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. | British journal of clinical pharmacology 20110801 |
| A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. | British journal of clinical pharmacology 20110801 |
| Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. | British journal of clinical pharmacology 20110801 |
| Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. | British journal of clinical pharmacology 20110801 |
| Fesoterodine stress degradation behavior by liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry. | Talanta 20110530 |
| Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. | BJU international 20110501 |
| Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. | Current medical research and opinion 20110501 |
| Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. | Current medical research and opinion 20110501 |
| Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. | Journal of clinical pharmacology 20110301 |
| Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. | Journal of the American Geriatrics Society 20110301 |
| Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. | BJU international 20110201 |
| Early onset of fesoterodine efficacy in subjects with overactive bladder. | BJU international 20110201 |
| Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. | Digestive diseases and sciences 20110101 |
| Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. | Urology 20101201 |
| Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? | BJU international 20100901 |
| The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. | BJU international 20100801 |
| Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. | The Journal of urology 20100801 |
| Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. | BJU international 20100701 |
| Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. | BJU international 20100501 |
| Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. | Urology 20100501 |
| Thorough QT study of the effect of fesoterodine on cardiac repolarization. | International journal of clinical pharmacology and therapeutics 20100501 |
| Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. | Current medical research and opinion 20100401 |
| Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. | International journal of clinical practice 20100401 |
| Durability of treatments for overactive bladder. | International journal of clinical practice 20100401 |
| The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. | European journal of clinical pharmacology 20100201 |
| New Drugs2010, PART 1. | Nursing 20100201 |
| Fesoterodine fumarate. | Drugs of today (Barcelona, Spain : 1998) 20100201 |
| Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. | Urology 20100101 |
| Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. | BJU international 20100101 |
| Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. | BMC urology 20100101 |
| Determination of fesoterodine in pharmaceutical formulations by using liquid chromatography-tandem mass spectrometry. | European journal of mass spectrometry (Chichester, England) 20100101 |
| Fesoterodine for the treatment of overactive bladder. | The Annals of pharmacotherapy 20091201 |
| Tolterodine extended-release for overactive bladder. | Expert opinion on pharmacotherapy 20090901 |
| Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. | International journal of clinical pharmacology and therapeutics 20090901 |
| Fesoterodine for the treatment of overactive bladder. | The Nurse practitioner 20090801 |
| Efficacy and tolerability of fesoterodine in women with overactive bladder. | International urogynecology journal and pelvic floor dysfunction 20090701 |
| Evaluation of drug-drug interactions with fesoterodine. | European journal of clinical pharmacology 20090601 |
| Influence of food on the pharmacokinetic profile of fesoterodine. | International journal of clinical pharmacology and therapeutics 20090601 |
| New drug information: Toviaz. | JAAPA : official journal of the American Academy of Physician Assistants 20090601 |
| Fesoterodine (toviaz) for overactive bladder. | The Medical letter on drugs and therapeutics 20090504 |
| Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. | Journal of clinical pharmacology 20090401 |
| Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. | International journal of clinical practice 20090401 |
| The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. | Swiss medical weekly 20090307 |
| Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. | The Journal of pharmacology and experimental therapeutics 20090301 |
| Fesoterodine: a new agent for treating overactive bladder. | The American journal of managed care 20090301 |
| New drugs: milnacipran hydrochloride, fesoterodine fumarate, and silodosin. | Journal of the American Pharmacists Association : JAPhA 20090101 |
| Fesoterodine. | Drugs 20090101 |
| The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. | Current medicinal chemistry 20090101 |
| Toviaz approved for overactive bladder. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081201 |
| Comparison of fesoterodine and tolterodine in patients with overactive bladder. | BJU international 20081101 |
| Pharmacokinetic profile of fesoterodine. | International journal of clinical pharmacology and therapeutics 20081101 |
| Impact of fesoterodine on quality of life: pooled data from two randomized trials. | BJU international 20080701 |
| Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. | Expert opinion on pharmacotherapy 20080701 |
| Fesoterodine dose response in subjects with overactive bladder syndrome. | Urology 20080501 |
| Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. | BJU international 20080401 |
| Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. | European urology 20071001 |